NEWSLETTER MARCH 2020
Designing the framework for a new European paediatric research infrastructure
Dear Colleagues,
I am pleased to welcome you to the sixth newsletter of the EPTRI project.
As you know, after two years of intense and fruitful work, we are approaching to the final phases of the project. However, the next months must not be absolutely considered as the end of our work, but rather a new start to build the European Paediatric Translational Research Infrastructure.
Several steps forward have been made during the feasibility phase of EPTRI, where several studies have been submitted and evaluated by the Advisory Board.
Within the Thematic Research Platform dedicated to Developmental Pharmacology, two feasibility study proposals have been submitted with the aim to investigate the feasibility and sustainability of EPTRI services, facilities, expertise needed for completing the studies in the field of placental platform use and model-based algorithms for adjusting dosing therapy.
The services to be provided and the potentialities of the Developmental Pharmacology Platform, that will involve multiple experts like pharmacologists, clinicians, chemists, toxicologists and regulators, have been described in the deliverable that will be part of the final EPTRI Conceptual Design Report (CDR).
Strengthened by this collaborative environment and strong commitment, we are ready to boost the paediatric drugs development processes in collaboration with the other EPTRI thematic research platforms.
Saskia de Wildt
Leader of the EPTRI Developmental Pharmacology Platform
Save the date - EPTRI Open Meeting, April 2-3 in Brussels (The President Brussels Hotel)
EPTRI is now a friend of the Rare Disease Day
EPTRI recently became a friend of Rare Disease Day, an initiative organized by Eurordis that aims at raising awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. Rare Disease Day took place on the last day of February each year.
EPTRI at the Health-RI Conference 2020 in Utrecht
We all want to stay healthy for as long as possible but how do we manage to do this? How can we learn from today’s patients so that tomorrow’s patients receive better treatments? This is generally a matter of continuous learning and improvement – evidence based with the help of enormous amounts of data in different formats and from various sources.
EPTRI participation in the innovation and SME forum
On November 27th (2019), the EPTRI Coodinator, Donato Bonifazi, was invited to present EPTRI at the Innovation and SME Forum in Milan.
The Forum was organised by ELIXIR Italy, Assobiotec and AREA Science Park. It was focused on the topic “Data management in the life sciences – a driver for innovation” with the aim of providing information on ELIXIR resources and creating a space for networking between industry and academia in a world of data-driven innovation, with a mix of high-level keynote presentations and hands-on sessions to discuss and interact with other companies, academics and ELIXIR partners.
EPTRI at the National Conference of the Italian Society of Pharmacology
The 39th National Conference of the Italian Society of Pharmacology (SIF) was held in Florence on November 20th-23rd 2019. The event was the occasion to enrich the knowledge and skills on the world of pharmaceuticals that is on constant evolution.
EPTRI at MIBio 2019
Elisa Alessandrini, from University College London (UCL), recently attended the 9th annual MIBio conference on behalf of the EPTRI consortium. The event took place at Downing College (Cambridge) on the 13th of November. Elisa presented a poster about the EPTRI project focusing on the expertise and gaps in the paediatric formulation science area.
EPTRI at the 4th annual conference of the ELIXIR Czech National Node
Mariangela Lupo, member of the EPTRI coordination team at Consorzio per Valutazioni Biologiche e Farmacologiche (CVBF) and Fedele Bonifazi, President of the Gianni Benzi Foundation and leader of WP4, were invited to take part in the 4th Annual Conference of the ELIXIR Czech National Node that was held on 11-12th November in Kurdějov (Czech Republic).
EPTRI attended the 16th DIA Japan Annual Meeting
On November 10th-12th EPTRI was presented at the DIA Japan Annual Meeting 2019, held in Tokyo (Japan) at the Tokyo Big Sight on the topic “In order to deliver rational medicine for all people in the globe”.
The aim of the meeting was to provide the answer to the following question: What can and should we do for patients, future patients and the patient families?
EVENTS OF INTEREST
March 4th, Brussels, Belgium.
EOSC-Life brings together the 13 Biological and Medical ‘ESFRI’ research infrastructures (BMS RIs) to create an open, digital and collaborative space for biological and medical research. At this meeting results from the first year will be presented and next steps will be discussed.
March 9-11th 2020, Berlin, Germany.
This meeting addresses innovative solutions to the greatest challenges in pharmaceutical development. The agenda includes both speakers from the industry and academia. Some of the themes to be discussed on the summit include personalised therapies, mRNA, cell and gene therapies, analytical techniques for biotherapeutics, 3D printing and oral drug delivery.
March 17-19th, Brussels, Belgium.
This annual event spans DIA’s strategic initiatives across a range of thought leadership streams – clinical development & operations, regulatory science, value and access, patient engagement, translational medicine and many more.
March 23-24th 2020, Cape Town, South Africa.
This symposium will bring together research infrastructures from Africa and Europe to build sustainable scientific collaborations. Attendees will include representatives from relevant funding agencies as well as policy makers to join and discuss opportunities for working together.
March 26-27th 2020, Madrid, Spain.
This conference aims to bring together leading academic scientists, researchers and research scholars to exchange and share their experiences and research results on all aspects of Innovation in Drug Discovery Technology.